Core Insights - The company reported a revenue of 183 million yuan for the first half of 2025, representing a year-on-year growth of 19.77% [1] - The net profit attributable to shareholders reached 54 million yuan, with a year-on-year increase of 40.91% [1] - The company achieved a non-recurring net profit of 47 million yuan, reflecting a year-on-year growth of 22.08% [1] Financial Performance - In Q2 2025, the company generated a revenue of 99 million yuan, marking a year-on-year growth of 30.81% and a quarter-on-quarter increase of 18.49% [2] - The net profit attributable to shareholders for Q2 was 30 million yuan, showing a significant year-on-year increase of 110.68% and a quarter-on-quarter growth of 25.94% [2] - The rapid growth in net profit is attributed to increased revenue and effective dilution of fixed costs due to business scale expansion, leading to a notable improvement in overall net profit margin [2] R&D and Innovation - The company is accelerating its R&D efforts, optimizing various coating and modification processes for its products [3] - New products developed during the reporting period have been successfully applied in clinical and production replacement projects [3] - The company has established a unique core technology platform encompassing microbead synthesis, surface modification, and functional modification technologies related to pharmaceutical separation and purification [3] Investment Outlook - The company is rated as "Accumulate," with expected EPS of 0.23 yuan and 0.29 yuan for 2025 and 2026, respectively [3] - The company is one of the few globally with advanced R&D and large-scale production capabilities in both analytical chromatography and industrial purification media [3]
赛分科技(688758)：Q2业绩增速同比改善